Sorrento Therapeutics Inc (SRNE): SCILEX PORTFOLIO ZTlido® (lidoca...

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	57
Posts	5700
Boards Moderated	0
Alias Born	12/13/2004

dia76ca

Re: 1776club post# 11884

Monday, 11/08/2021 10:43:10 AM

Monday, November 08, 2021 10:43:10 AM

SCILEX PORTFOLIO

ZTlido® (lidocaine topical system) 1.8%
(Post-herpetic Neuralgia-PHN, Shingles pain)
Approved and Launched October 2018
SP-102
(Lumbar Radicular/Sciatica Pain)
Phase 3 trial enrollment completed in 2H 2021
SP-103
Lidocaine Topical System 5.4% (3X)(Acute Low Back Pain)
Initiating Phase 2 in 2H 2021
SP-104
Delayed Burst Release Low Dose Naltrexone (Fibromyalgia)
Initiating Phase 1 in 2H 2021

Scilex could very well be spun off. It is a company within a company. It has a marketed product, a blockbuster phase 3, other huge potential phase 2 and phase 1 products.
https://www.scilexpharma.com/

"The refusal of the real is the number one dogma of our time" Rene Girard

Keep Last Read

Replies (1) Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Detailed Quote

Recent SRNE News

Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 09:31:06 PM
Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2023 08:15:31 PM
Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2023 01:51:06 AM
Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2023 09:25:07 PM
Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/07/2023 08:15:35 PM
Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2023 10:01:54 AM
Form 8-K - Current report • Edgar (US Regulatory) • 07/13/2023 10:26:26 AM